Pfizer on Friday has applied for full regulatory approval in Brazil of its COVID-19 vaccine developed with BioNTech SE, Brazilian health regulator Anvisa said on Saturday, reported Reuters.

Now, Pfizer is the second vaccine submitted for registration in Brazil, after AstraZeneca applied on Jan. 29. Pfizer’s vaccine is backed up by late-stage trials on 44,000 volunteers in six countries and 2,900 of them are in Brazil.

According to Reuters, Pfizer’s vaccine has an overall efficacy of 95%, and efficacy of 94% in people aged over 65.